Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat
Blood (2016)
  • John M. Pagel, Cancer Institute
  • Megan Othus, Fred Hutchinson Cancer Research Center
  • Guillermo Garcia-Manero, University of Texas MD Anderson Cancer Center
  • Min Fang, Fred Hutchinson Cancer Research Center
  • Jerald P. Radich, Fred Hutchinson Cancer Research Center
  • David A. Rizzieri, Duke University
  • Guido Marcucci, Ohio State University
  • Stephen A. Strickland, Vanderbilt University
  • Mark Litzow, Mayo Clinic
  • Mary Lynn Savoie, Alberta Health Services
  • Stephen R. Spellman, Center for International Blood and Marrow Transplant Research
  • Dennis L. Confer, National Marrow Donor Program
  • Jeffrey Chell, National Marrow Donor Program
  • Maria Brown, Center for International Blood and Marrow Transplant Research
  • Bruno C. Medeiros, Stanford University
  • Mikkael A. Sekeres, Cleveland Clinic
  • Tara L. Lin, University of Kansas
  • Geoffrey L. Uy, Washington University in St. Louis
  • Bayard L Powell, Wake Forest University
  • Jonathan E. Kolitz, Hofstra University
  • Richard A. Larson, University of Chicago
  • Richard M. Stone, Harvard University
  • David F. Claxton, Penn State Cancer Institute
  • James Essell, Jewish Hospital
  • Selina Luger, University of Pennsylvania
  • Sanjay R. Mohan, Vanderbilt University Medical Center
  • Anna Moseley, Fred Hutchinson Cancer Research Center
  • Harry P. Erba, University of Alabama at Birmingham
  • Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
December 2, 2016
Citation Information
John M. Pagel, Megan Othus, Guillermo Garcia-Manero, Min Fang, et al.. "Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat" Blood Vol. 128 Iss. 22 (2016) p. 1166 - 1166
Available at: http://works.bepress.com/john-pagel/38/